Drug Trial Radar · NCT07235033
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jan 23, 2024
Primary completion
Mar 5, 2025
Study completion Mar 19, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
Conditions
- Uncomplicated Plasmodium Falciparum Malaria
Interventions
KAE609Drug
oral capsules administered in combination with KLU156
SoC (Coartem)Drug
Standard of Care
KLU156Drug
oral sachet formulation (KAF156+LUM-SDF) administered in combination with cipargamin (KAE609)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Polymerase Chain Reaction (PCR) Corrected Adequate Clinical and Parasitological Response (ACPR)Time frame: Day 29
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Abidjan, Côte d’Ivoire
Novartis Investigative Site
Libreville, Gabon
Novartis Investigative Site
Ahero, Kenya
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.